机构：[a]Peking University People’s Hospital, Beijing, China[b]Nanfang Hospital, Southern Medical University, Guangzhou, China[c]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[d]Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China深圳市第二人民医院深圳医学信息中心[e]The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Henan, China[f]Xuanwu Hospital, Capital Medical University, Beijing, China首都医科大学宣武医院[g]Xi Jing Hospital, The Fourth Military Medical University, Shanxi, China[h]Second Hospital of Shanxi Medical University, Shanxi, China[i]Beijing Anzhen Hospital, Capital Medical University, Beijing, China首都医科大学附属安贞医院[j]Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China[k]Shengjing Hospital Affiliated to China Medical University, Shenyang, China中国医科大学盛京医院[l]Changhai Hospital, Second Military Medical University, Shanghai, China[m]First Hospital of Shanxi Medical University, Shanxi, China[n]Kaifeng Central Hospital, Henan, China[o]Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China[p]The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China[q]The First Affiliated Hospital of Xi’an Jiaotong University, Shanxi, China[r]Qiqihar First Hospital, Heilongjiang, China[s]The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, China[t]The Affiliated Hospital of Qingdao University, Qingdao, China Shandong[u]The First Affiliated Hospital of College of Medicine, Zhejiang University, Zhejiang, China浙江大学医学院附属第一医院[v]Fujian Medical University Union Hospital, Fujian, China[w]Shandong University Qilu Hospital, Shandong, China[x]Institute of Hematology & Affiliated Hospital, Medicine School, Northwestern University, Shan’xi, China[y]Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China[z]Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
We explored variables associated with patient-reported outcomes (PROs) including symptom burden, impact on daily life and work, obstacles during therapy, satisfaction level with therapy, and health-related quality of life in 1500 respondents with myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF) in a multicenter, cross-sectional study across China, a representative of the developing countries. In multivariate analyses, urban household registration and higher education level were significantly-associated with no symptoms at diagnosis in respondents with ET or MF. CALR mutation was significantly-associated with lower MPN-10 scores in respondents with MF. Higher MPN-10 scores were significantly-associated with negative impact on daily life and work as well as lower satisfaction level in respondents with ET, PV and MF. Receiving ruxolitinib was significantly-associated with high satisfaction and satisfaction in respondents with MF. In addition, other demographics and clinical variables were also impacting PROs.
基金：
This study was funded by the National Natural Science
Foundation of China [No. 81770161, 81970140].
第一作者机构：[a]Peking University People’s Hospital, Beijing, China
共同第一作者：
通讯作者：
通讯机构：[a]Peking University People’s Hospital, Beijing, China[y]Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China[z]Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China[*1]Peking University People’s Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Beijing 100044, China[*2]Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China[*3]Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
推荐引用方式(GB/T 7714)：
Dayu Shi,Hongxia Shi,Xiaoli Liu,et al.Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms[J].LEUKEMIA & LYMPHOMA.2021,62(11):2703-2715.doi:10.1080/10428194.2021.1933481.
APA：
Dayu Shi,Hongxia Shi,Xiaoli Liu,Minghui Duan,Junling Zhuang...&Qian Jiang.(2021).Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms.LEUKEMIA & LYMPHOMA,62,(11)
MLA：
Dayu Shi,et al."Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms".LEUKEMIA & LYMPHOMA 62..11(2021):2703-2715
